Vital-Imi
  • HOME
  • ABOUT
    • PARTNERS
    • WORK PACKAGES
      • Work Package 1
      • Work Package 2
      • Work Package 3
      • Work Package 4
      • Work Package 5
  • PUBLICATIONS
  • UPDATES
  • MENU
    • EVENTS
    • PARTNERS
    • NEWSLETTER
    • CONTACT
    • PRIVACY POLICY
    • LOGIN
  • Search
  • Menu Menu

Archive for: Publications

Identification of aging-associated immunotypes and immune stability as indicators of post-vaccination immune activation

Using qualitative research to develop an elaboration of the TIDieR checklist for interventions to enhance vaccination communication: short report

Vaccines and Vaccination against SARS-CoV-2: Considerations for the Older Population

Vaccination of older adults: Influenza, pneumococcal disease, herpes zoster, COVID-19 and beyond

Exploratory Analysis of the Economically Justifiable Price of a Hypothetical RSV Vaccine for Older Adults in the Netherlands and the United Kingdom

Healthcare Workers’ Perceptions and Experiences of Communicating with People over 50 about Vaccination

European data sources for computing burden of (potential) vaccine-preventable diseases in ageing adults

Cost-Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in the Dutch National Influenza Prevention Program

Health Economics of Vaccines: From Current Practice to Future Perspectives

Cost-Effectiveness of Pediatric Influenza Vaccination in The Netherlands

Page 1 of 212

Pages

  • About
  • Contact
  • Events
  • Homepage
  • Join Us
  • Member Area
  • Member Login
  • MENU
  • NEWSLETTER
  • Partners
  • Password Reset
  • Privacy Policy
  • Profile
  • PUBLICATIONS
  • Registration
  • Test Page
  • Updates
  • Work Package 1
  • Work Package 1 – member area
  • Work Package 2
  • Work Package 2 – member area
  • Work Package 3
  • Work Package 3 – member area
  • Work Package 4
  • Work Package 4 – member area
  • Work Package 5
  • Work Package 5 – member area

Categories

  • No categories

Archive

    Contact

    You can contact us by using the contact form here.

    Follow us

    • twitter

    The VITAL project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806776. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

    Scroll to top